<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 19, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00000160</url>
  </required_header>
  <id_info>
    <org_study_id>NEI-62</org_study_id>
    <nct_id>NCT00000160</nct_id>
  </id_info>
  <brief_title>Diabetic Retinopathy Study (DRS)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Eye Institute (NEI)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether photocoagulation helps prevent severe visual loss from proliferative
      diabetic retinopathy.

      To determine whether a difference exists in the efficacy and safety of argon versus xenon
      photocoagulation for proliferative diabetic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual
      disability in the United States.  The use of photocoagulation to treat proliferative
      retinopathy gained widespread use in ophthalmic practice following its introduction in 1959.
      However, only a few studies of photocoagulation incorporated any of the basic principles of
      controlled clinical trials, and these involved inadequate numbers of patients.
      Consequently, there has been inadequate evidence of the actual value of the procedure.
      Because of the clinical importance of diabetic retinopathy and the increasing use of
      photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971.
      This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15
      medical centers.

      One eye of each patient was randomly assigned to immediate photocoagulation and the other to
      followup without treatment, regardless of the course followed by either eye.  The eye chosen
      for photocoagulation was randomly assigned to either of two treatment techniques, one using
      an argon laser and the other a xenon arc photocoagulator.  Patients were followed at 4-month
      intervals according to a protocol that provided for measurement of best corrected visual
      acuity.

      Treatment was usually completed in one or two sittings and included scatter (panretinal)
      photocoagulation extending to or beyond the vortex vein ampulae.  The argon treatment
      technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct
      treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or
      outside this area (NVE).  Focal treatment was also applied to microaneurysms or other
      lesions thought to be causing macular edema.  Followup treatment was applied as needed at
      4-month intervals.  The xenon technique was similar, but scatter burns were fewer in number,
      generally of longer duration, and stronger, and direct treatment was applied only to NVE on
      the surface of the retina.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1972</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Primary Purpose: Treatment</study_design>
  <condition>Diabetic Retinopathy</condition>
  <condition>Blindness</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Xenon Photocoagulation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Argon Photocoagulation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photocoagulation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients were eligible if they had best corrected visual acuity of 20/100 or better in
        each eye and the presence of proliferative diabetic retinopathy in at least one eye or
        severe nonproliferative retinopathy in both eyes.  They could not have had prior treatment
        with photocoagulation or pituitary ablation, and both eyes had to be suitable for
        photocoagulation.  All eligible patients were younger than 70 years, and the examining
        physician assessed the outlook for survival and availability for 5 years of followup to be
        good.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.asp</url>
    <description>Clinical Alert to Ophthalmologistsâ€”Early Treatment Diabetic Retinopathy Study (ETDRS)</description>
  </link>
  <link>
    <url>http://www.nei.nih.gov/news/pressreleases/drspressrelease.asp</url>
    <description>NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy</description>
  </link>
  <reference>
    <citation>[No authors listed] Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 1981 Jul;21(1 Pt 2):1-226. No abstract available.</citation>
    <PMID>7195893</PMID>
  </reference>
  <reference>
    <citation>Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1979 Apr;97(4):654-5.</citation>
    <PMID>426679</PMID>
  </reference>
  <reference>
    <citation>The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979</citation>
  </reference>
  <reference>
    <citation>Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic retinopathy study report no. 5. Dev Ophthalmol. 1981;2:248-61.</citation>
    <PMID>7262408</PMID>
  </reference>
  <reference>
    <citation>Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981 Jul;88(7):583-600.</citation>
    <PMID>7196564</PMID>
  </reference>
  <reference>
    <citation>Ederer F, Podgor MJ. Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Control Clin Trials. 1984 Dec;5(4):373-81.</citation>
    <PMID>6394209</PMID>
  </reference>
  <reference>
    <citation>Rand LI, Prud'homme GJ, Ederer F, Canner PL. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10. Invest Ophthalmol Vis Sci. 1985 Jul;26(7):983-91.</citation>
    <PMID>2409053</PMID>
  </reference>
  <reference>
    <citation>Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976 Apr;81(4):383-96. PubMed PMID: 944535.</citation>
    <PMID>944535</PMID>
  </reference>
  <reference>
    <citation>Ferris FL 3rd, Podgor MJ, Davis MD. Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12. Ophthalmology. 1987 Jul;94(7):754-60.</citation>
    <PMID>3658347</PMID>
  </reference>
  <reference>
    <citation>Kaufman SC, Ferris FL 3rd, Swartz M. Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Arch Ophthalmol. 1987 Jun;105(6):807-9.</citation>
    <PMID>3555429</PMID>
  </reference>
  <reference>
    <citation>Kaufman SC, Ferris FL 3rd, Seigel DG, Davis MD, DeMets DL. Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Invest Ophthalmol Vis Sci. 1989 Jan;30(1):23-8.</citation>
    <PMID>2912911</PMID>
  </reference>
  <reference>
    <citation>The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253</citation>
  </reference>
  <reference>
    <citation>[No authors listed] Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology. 1978 Jan;85(1):82-106.</citation>
    <PMID>345173</PMID>
  </reference>
  <verification_date>October 2003</verification_date>
  <lastchanged_date>June 1, 2006</lastchanged_date>
  <firstreceived_date>September 23, 1999</firstreceived_date>
  <keyword>Vision Loss</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Blindness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
